CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 132 enrolled
Drug / intervention
Remimazolam +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05836545
NCT05836545Phase 3Completed

A Randomized, Single-Blind, Investigator Initiative Trial Study of Remimazolam Versus Midazolam for Sedation in Diagnostic Upper Gastrointestinal Endoscopy

Samsung Medical Center·interventional·Posted May 1, 2023·Updated Nov 18, 2025

In Brief

A Phase 3 clinical trial evaluating Remimazolam and Midazolam for Healthy. Completed, enrolled 132 participants across 1 site.

Detailed Summary

The goal of this clinical trial is to compare the efficacy of remimazolam with midazolam in patients undergoing gastrointestinal endoscopy. The main questions it aims to answer are: * Superiority of total procedure time in remimazolam compared to midazolam * The success of sedation time This is the single blind study.; Patients will not know what they are given as the sedation drug If there is a comparison group: Researchers will compare patients with midazolam group to see if remimazolam group is superior to midazolam group

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesSouth Korea
Collaborators--

Timeline

Phase 3CompletedFinished
202420252026
First PostedMay 1, 2023
Enrollment StartApr 5, 2023
Primary CompletionJan 6, 2024
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 3.2 years ago

Interventions

Remimazolamdrug

The patient with remimazolam

Midazolamdrug

The patient with midazolam